Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Published . Updated .
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China. The company al
Directly affected
Indirectly affected
- GIEQ GOLDMAN SACHS ETF TR DATA ENHA
GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- RACK VANECK ETF TR VANECK DATA CENT
GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-sever…
Source: Nasdaq Markets
How far Sagimet Biosciences (SGMT) has moved since 5 Oct 2026
Since the first closing price after “Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch,” Sagimet Biosciences (SGMT) is +1.14%. The S&P 500 fund (SPY) is -1.60% over the same days, a +2.75% difference versus the market.
Who gains and who loses around Sagimet Biosciences (SGMT)
Companies mentioned with this story
- SGMT Sagimet Biosciences
For “Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch,” Sagimet Biosciences (SGMT) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names SAGIMET BIOSCIENCES INC in the headline; GA resolved that company to SGMT
- GIEQ Goldman Sachs Etf Tr Data Enha
Goldman Sachs Etf Tr Data Enha (GIEQ) is linked, with no stored direction, medium confidence in the 5 Oct 2026 story “Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch.” Reason on file: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- RACK Vaneck Etf Tr Vaneck Data Cent
Vaneck Etf Tr Vaneck Data Cent (RACK) is linked, with no stored direction, medium confidence in the 5 Oct 2026 story “Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch.” Reason on file: GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Sagimet Biosciences (SGMT)
“Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch” (5 Oct 2026) reaches Sagimet Biosciences (SGMT) through this story.
The link for Sagimet Biosciences (SGMT) is this: The reported development directly names SAGIMET BIOSCIENCES INC in the headline; GA resolved that company to SGMT
A second company, Goldman Sachs Etf Tr Data Enha (GIEQ), is listed for a different reason: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Sagimet Biosciences (SGMT)
GIEQ traded between 41.01 and 42.36 across 6 sessions. The latest close on file is 41.10. RACK traded between 44.78 and 51.45 across 20 sessions. The latest close on file is 44.78. SGMT traded between 7.51 and 9.12 across 11 sessions. The latest close on file is 8.86.
What the saved facts support for Sagimet Biosciences (SGMT)
27 out of 100
“Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch” scores 27 out of 100. The score uses 1 sources, and 3 linked companies.